The International/Canadian hereditary angioedema guideline

Area of Science:

• Immunology
• Genetics
• Internal Medicine

Background:

• Hereditary Angioedema (HAE) causes unpredictable swelling attacks with significant morbidity and mortality risk.
• Current HAE management is often inconsistent and suboptimal globally, necessitating updated guidelines.
• The 2019 Canadian HAE Guideline is updated to address worldwide patient management.

Purpose of the Study:

• To provide evidence-based recommendations for Hereditary Angioedema (HAE) management.
• To offer guidance on treating HAE attacks, prophylaxis, and comprehensive care.
• To expand the guideline's scope for international application and include new patient populations.

Main Methods:

• Development through collaboration of Canadian and international HAE experts and patient groups.
• Utilized the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for evidence-based recommendations.
• Incorporated new sections on breastfeeding/lactating patients and shared decision-making.

Main Results:

• Provides recommendations for HAE attack treatment, short-term and long-term prophylaxis.
• Includes guidance on self-administration, individualized therapy, quality of life, and comprehensive care.
• New recommendations address HAE management in breastfeeding individuals and shared decision-making.

Conclusions:

• The updated guideline aims to optimize Hereditary Angioedema (HAE) management globally.
• Emphasizes the importance of individualized care and comprehensive strategies for HAE patients.
• Serves as a resource for healthcare providers, policymakers, patients, and advocates to improve HAE care delivery.